Want to see HK:2493 full AI Analyst Report?
Total Valuation
Mabwell (Shanghai) Bioscience Co., Ltd. Class H has a market cap or net worth of HK$17.84B. The enterprise value is HK$11.83K.
Market CapHK$17.84B
Enterprise ValueHK$11.83K
Share Statistics
Mabwell (Shanghai) Bioscience Co., Ltd. Class H has 47,130,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding47,130,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Mabwell (Shanghai) Bioscience Co., Ltd. Class H’s return on equity (ROE) is -2.77 and return on invested capital (ROIC) is -27.74%.
Return on Equity (ROE)-2.77
Return on Assets (ROA)-0.21
Return on Invested Capital (ROIC)-27.74%
Return on Capital Employed (ROCE)-0.42
Revenue Per Employee500.01K
Profits Per Employee-733.78K
Employee Count1,325
Asset Turnover0.15
Inventory Turnover0.34
Valuation Ratios
The current PE Ratio of Mabwell (Shanghai) Bioscience Co., Ltd. Class H is ―. Mabwell (Shanghai) Bioscience Co., Ltd. Class H’s PEG ratio is 1.42.
PE Ratio―
PS Ratio14.37
PB Ratio27.25
Price to Fair Value27.25
Price to FCF-21.26
Price to Operating Cash Flow-9.18
PEG Ratio1.42
Income Statement
In the last 12 months, Mabwell (Shanghai) Bioscience Co., Ltd. Class H had revenue of 662.52M and earned -969.33M in profits. Earnings per share was -2.43.
Revenue662.52M
Gross Profit598.05M
Operating Income-955.32M
Pretax Income-956.39M
Net Income-969.33M
EBITDA-647.88M
Earnings Per Share (EPS)-2.43
Cash Flow
In the last 12 months, operating cash flow was -764.00M and capital expenditures -133.66M, giving a free cash flow of -897.77M billion.
Operating Cash Flow-764.00M
Free Cash Flow-897.77M
Free Cash Flow per Share-19.05
Dividends & Yields
Mabwell (Shanghai) Bioscience Co., Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.09
52-Week Price Change-25.32%
50-Day Moving Average22.89
200-Day Moving Average―
Relative Strength Index (RSI)45.57
Average Volume (3m)321.97K
Important Dates
Mabwell (Shanghai) Bioscience Co., Ltd. Class H upcoming earnings date is Oct 22, 2026, TBA (Not Confirmed).
Last Earnings DateAug 30, 2026
Next Earnings DateOct 22, 2026
Ex-Dividend Date―
Financial Position
Mabwell (Shanghai) Bioscience Co., Ltd. Class H as a current ratio of 0.90, with Debt / Equity ratio of 383.90%
Current Ratio0.90
Quick Ratio0.82
Debt to Market Cap0.26
Net Debt to EBITDA-1.66
Interest Coverage Ratio-10.52
Taxes
In the past 12 months, Mabwell (Shanghai) Bioscience Co., Ltd. Class H has paid 15.86M in taxes.
Income Tax15.86M
Effective Tax Rate-0.02
Enterprise Valuation
Mabwell (Shanghai) Bioscience Co., Ltd. Class H EV to EBITDA ratio is -16.36, with an EV/FCF ratio of -23.66.
EV to Sales15.99
EV to EBITDA-16.36
EV to Free Cash Flow-23.66
EV to Operating Cash Flow-36.51
Balance Sheet
Mabwell (Shanghai) Bioscience Co., Ltd. Class H has HK$2.29B in cash and marketable securities with HK$3.35B in debt, giving a net cash position of -HK$1.06B billion.
Cash & Marketable SecuritiesHK$2.29B
Total DebtHK$3.35B
Net Cash-HK$1.06B
Net Cash Per Share-HK$22.51
Tangible Book Value Per ShareHK$0.67
Margins
Gross margin is 74.55%, with operating margin of -144.20%, and net profit margin of -146.31%.
Gross Margin74.55%
Operating Margin-144.20%
Pretax Margin-144.36%
Net Profit Margin-146.31%
EBITDA Margin-97.79%
EBIT Margin-130.65%
Analyst Forecast
The average price target for Mabwell (Shanghai) Bioscience Co., Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast385.38%
EPS Growth Forecast―